In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals in Depth: May 2010

Executive Summary

Alliance leaders included GSK's €73.9 million investment in new partner Dong-A Pharmaceutical and Medtronic's $70 million investment in cardiovascular device company BioControl. Abbott led biopharma M&A activity with its $3.7 billion purchase of Piramal's healthcare solutions business. In devices, Endo paid $221 million up front for HealthTronics. Roughly 30 percent of the month's $953 million in biopharma fundraising came from Salix's $291 million debt deal. No public device dollars were realized in May, though 11 companies completed venture rounds.

You may also be interested in...



FDA Details Alternatives For COVID-19 Test Supplies

The US agency has released a document explaining what COVID-19 testing supplies may be substituted.

Curecumin Piques US Consumers’ Interest; UK Curiosity Grows For Omega-3, Survey Shows

Marketing consultant Buzzback surveyed 800 consumers in March, prior to novel coronavirus shutdowns in the two countries, to identify ingredients that offer opportunities for brands in health care, wellness and skin care.

AstraZeneca Links With Accent To Target RNA-Modifying Proteins

AstraZeneca and Accent Therapeutics will jointly discover, develop and commercialize novel therapeutics targeting RNA-modifying proteins for the treatment of cancer.

Topics

UsernamePublicRestriction

Register

CO200859

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel